Premium
Expression of the co‐stimulatory molecule B7 on melanoma cells
Author(s) -
Hersey Peter,
Si Zhaoyi,
Smith Melanie J.,
Thomas Wayne D.
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910580413
Subject(s) - melanoma , flow cytometry , cell culture , monoclonal antibody , cd28 , microbiology and biotechnology , messenger rna , biology , receptor , antigen , cancer research , cell , antibody , immunology , gene , cd8 , biochemistry , genetics
The induction of T‐cell responses against tumor cells is believed to depend on both recognition of antigen and receipt of co‐stimulatory signals from interaction of ligands such as B7 with its receptors CD28 or CTLA‐4 on T cells. In the present study the expression of B7 on cultured human melanoma cells was studied at the mRNA level by reverse PCR analysis and surface expression by flow cytometric analysis with monoclonal antibodies (MAbs). PCR analysis revealed mRNA for B7 in 3 of 6 (50%) cultured primary melanoma and 8 of 19 (42%) cultures of metastatic melanoma. Analysis of B7 expression by flow cytometry using the BBI MAb revealed low levels of expression in 3 of 10 melanoma that had mRNA for B7. In 2 of the latter (but not 4 other PCR + lines) expression could be increased by culture in GM‐CSF, IL‐2, IFN‐γ and IFN‐α2. Our results indicate that although mRNA for B7 is present in 40‐50% of melanoma cell lines, expression at the protein level is at low or undetectable levels in the majority of the cell lines. Expression of B7 protein was also not detected in studies on tissue sections from 11 primary and 9 metastatic melanomas.